Taking people in GermanyPhase 2
Cevostamab with Pomalidomide and Dexamethasone for Previously Treated Multiple Myeloma
Tests cevostamab with pomalidomide and dexamethasone in adults with multiple myeloma after CAR T-cell therapy.
Key facts
- Who runs it
- Hoffmann-La Roche
- Where
- Berlin, Bonn, Chemnitz, Cologne, Dresden, Erlangen, Essen, Greifswald, Hamburg, Hanover, Heidelberg, Jena, Kiel, Munich, Nuremberg, Oldenburg, Regensburg, Ulm, and Wuerzburg, GermanySee the 20 sites
- Trial code
- Registry title
- Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 45 people, planned
- Started
- 3 Nov 2026
- Expected to end
- 19 Jan 2031
- Type of study
- Interventional
- Treatments tested
- Cevostamab
- Pomalidomide
- Dexamethasone
- Tocilizumab
- Record updated
- 5 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with multiple myeloma who have had one to four earlier treatments, including a BCMA-targeting CAR T-cell therapy.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Multiple myeloma diagnosed by the International Myeloma Working Group criteria, with measurable disease at screening. ECOG performance status of 0 or 1.
- Earlier treatment
- One to four earlier lines of therapy, including a BCMA-targeting CAR T-cell therapy. Must also have had an anti-CD38 therapy, a proteasome inhibitor and lenalidomide in any earlier line.
Main reasons for not taking part
- History of amyloidosis
- Plasma cell leukemia, or more than 500 circulating plasma cells per µL or 5% of white blood cells in the blood
- Severe allergic or anaphylactic reaction to antibody therapy, or known allergy to an ingredient of cevostamab
- Stomach or bowel disease that could change how oral drugs are absorbed
- Known active central nervous system involvement or signs of meningeal involvement by myeloma
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 at screening and immediately prior to the start of administration of study treatment
- Received one to four lines of prior therapy, including prior B-cell maturation antigen (BCMA)-targeting Chimeric Antigen Receptors (CAR) T-cell therapy
- Multiple Myeloma diagnosis according to the International Myeloma Working Group (IMWG) diagnostic criteria
- Is triple-class exposed, i.e. received anti- cluster of differentiation 38 (CD38) therapy, a proteasome inhibitor (PI) and lenalidomide in any prior line
- Participants must have measurable disease during screening
Who cannot take part
- History of severe allergic or anaphylactic reactions to mAb therapy (or recombinant antibody-related fusion proteins) or known hypersensitivity to any of the excipients of cevostamab
- Gastrointestinal (GI) disease that might significantly alter absorption of oral drugs
- Known history of amyloidosis (e.g., positive Congo Red stain or equivalent in tissue biopsy or documented within serum amyloid P component scan)
- Plasma cell leukemia or circulating plasma cell count exceeding 500 cells/µL or 5% of the peripheral blood white cells
- Known active Central Nervous System (CNS) involvement, or exhibits clinical signs of meningeal involvement of MM. If either is suspected, negative whole-brain MRI and lumbar cytology are required
Where in Germany
- Charite Universitaetsmedizin Berlin KöRBerlin, GermanyTaking people
- HELIOS Klinikum Berlin Buch GmbHBerlin, GermanyTaking people
- Universitaetsklinikum Bonn AöRBonn, GermanyTaking people
- Klinikum Chemnitz gGmbHChemnitz, GermanyTaking people
- Universitaetsklinikum Koeln AöRCologne, GermanyTaking people
- Technische Universitaet DresdenDresden, GermanyTaking people
- Universitaetsklinikum Erlangen AöRErlangen, GermanyTaking people
- Universitaetsklinikum Essen (AoR)Essen, GermanyTaking people
- Universitaetsmedizin Greifswald KöRGreifswald, GermanyTaking people
- University Medical Center Hamburg-EppendorfHamburg, GermanyTaking people
- Medizinische Hochschule HannoverHanover, GermanyTaking people
- Universitaetsklinikum Heidelberg AöRHeidelberg, GermanyTaking people
- Universitaetsklinikum Jena KöRJena, GermanyTaking people
- Universitaetsklinikum Schleswig-Holstein AöRKiel, GermanyTaking people
- Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)Munich, GermanyTaking people
- Klinikum NuernbergNuremberg, GermanyTaking people
- Klinikum Oldenburg AorOldenburg, GermanyTaking people
- Universitaetsklinikum Regensburg AöRRegensburg, GermanyTaking people
- Universitaetsklinikum Ulm AoRUlm, GermanyTaking people
- Universitaetsklinikum Wuerzburg AöRWuerzburg, GermanyTaking people
About the trial
What the trial wants to find out
The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) in patients with multiple myeloma (MM) who have received one to four prior lines of therapy and have been exposed to an anti-cluster of differentiation 38 (CD38) antibody, lenalidomide, a proteasome inhibitor (PI) and a B cell maturation antigen (BCMA)-targeting chimeric antigen receptor (CAR) T-cell therapy.
The group in the trial
- Cevostamab plus Pomalidomide and Dexamethasone (Pd)Treatment being tested
Cevostamab will be combined with pomalidomide and dexamethasone as the experimental treatment in this study. Participants will receive Cevostamab as per the schedule in the protocol.
Treatment: Cevostamab, Pomalidomide, Dexamethasone, and Tocilizumab
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
- Official title
- A Phase II, Single Arm, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Cevostamab in Combination With Pomalidomide and Dexamethasone in Patients With Multiple Myeloma Who Have Received a Prior BCMA-Targeting CAR T-Cell Therapy
- Plain-language title
- Cevostamab with Pomalidomide and Dexamethasone for Previously Treated Multiple MyelomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 5 November 2026